HC Wainwright Reaffirms “Buy” Rating for MetaVia (NASDAQ:MTVA)

MetaVia (NASDAQ:MTVAGet Free Report)‘s stock had its “buy” rating reiterated by stock analysts at HC Wainwright in a note issued to investors on Friday,Benzinga reports. They presently have a $12.00 price target on the stock. HC Wainwright also issued estimates for MetaVia’s FY2029 earnings at ($5.01) EPS.

MetaVia Price Performance

Shares of MTVA stock opened at $1.55 on Friday. MetaVia has a 12 month low of $1.29 and a 12 month high of $5.30. The stock’s 50 day simple moving average is $1.70.

MetaVia Company Profile

(Get Free Report)

MetaVia Inc is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc, formerly known as NeuroBo Pharmaceuticals Inc, is based in CAMBRIDGE, Mass.

Featured Stories

Receive News & Ratings for MetaVia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MetaVia and related companies with MarketBeat.com's FREE daily email newsletter.